Streptococcus agalactiae in Aquaculture: Prevalence, Genotyping, and Vaccine Development

Introduction

Streptococcus agalactiae (group B Streptococcus, GBS) is a Gram-positive, beta-hemolytic coccus capsulated by a polysaccharide layer that facilitates adhesion to host epithelia and evasion of phagocytosis. Although historically recognized as a causative agent of mastitis in dairy cattle and neonatal sepsis in humans, S. agalactiae has emerged as a dominant bacterial pathogen in warm-water aquaculture, particularly in Nile tilapia (Oreochromis niloticus) and other cichlid species. Outbreaks of streptococcosis in farmed tilapia result in substantial economic losses due to high morbidity, mortality, and reduced feed conversion efficiency. The pathogen is transmitted horizontally through water and contaminated feed; fish become infected via the gills, gastrointestinal tract, or skin abrasions. Clinical signs include exophthalmia, corneal opacity, erratic swimming, and meningoencephalitis. The disease manifests as a septicemic process, with bacterial dissemination to the brain, kidney, spleen, and liver.

This article reviews the global prevalence of S. agalactiae in aquaculture, the molecular genotyping tools used for epidemiological surveillance, and the current landscape of vaccine development with a focus on multi-locus sequence typing (MLST) and autogenous vaccine strategies.

Prevalence in Aquaculture Systems

S. agalactiae has been isolated from farmed fish across tropical and subtropical regions, including Southeast Asia, South America, the Middle East, and parts of Africa. Prevalence rates vary by geographical region, water temperature, stocking density, and biosecurity practices. In tilapia farms, clinical outbreaks are commonly observed when water temperatures exceed 28 degrees Celsius; the pathogen proliferates rapidly under warm, hypereutrophic conditions. Reported prevalence in clinically diseased populations ranges from 30% to 80% depending on diagnostic method and sampling strategy [1, 2]. Asymptomatic carrier fish may harbor the bacterium in the hindgut and spleen, contributing to horizontal transmission and recrudescence during stress events [3].

Molecular surveys using species-specific PCR targeting the cfb gene (encoding CAMP factor) or the sip gene (surface immunogenic protein) have confirmed that S. agalactiae accounts for the majority of streptococcal infections in tilapia, outcompeting Streptococcus iniae and Lactococcus garvieae in many regions [4, 5]. A meta-analysis of diagnostic reports from Asia indicates that S. agalactiae constitutes approximately 65% to 85% of cultured isolates from diseased tilapia [6]. Coinfections with other bacterial or parasitic agents are common and complicate clinical diagnosis; see also Streptococcosis in Farmed Tilapia: Streptococcus agalactiae and Streptococcus iniae Pathogenesis, Rapid Diagnostic Tests, and Vaccine Development for a comparative discussion.

Genotyping Methods and Serotype Distribution

Multi-Locus Sequence Typing (MLST)

MLST is the gold standard for molecular epidemiological characterization of S. agalactiae. The scheme indexes seven housekeeping genes: adhP, pheS, atr, glnA, sdhA, gki, and tkt. Sequence types (STs) are assigned based on allelic profiles. In aquaculture isolates, the predominant clonal complexes are CC103 and CC17, with ST-103 and ST-260 being the most frequently reported sequence types globally [7, 8]. Importantly, ST-103 strains are almost exclusively associated with fish hosts and are rarely encountered in human or bovine populations, suggesting a host-adapted lineage. Whole-genome phylogenies have resolved ST-103 into several subclades that correlate with serotype and geographic origin [9].

The application of MLST has enabled tracking of transmission pathways across farms and regions. For instance, ST-260 strains from Southeast Asia share a common ancestor with ST-103 strains from South America, indicating transcontinental dissemination through fish trade [10]. MLST also informs vaccine strain selection. Because immunity is largely serotype-specific, a vaccine must match the predominant ST and serotype in a target region.

Serotype Classification

S. agalactiae is classified into ten serotypes (Ia, Ib, II through IX) based on capsular polysaccharide (CPS) structure. In fish, serotype Ia and serotype III are most prevalent. Serotype Ia ST-103 is the dominant clone in Asian and South American tilapia farms; serotype III strains, often belonging to ST-17, are occasionally isolated but are more common in human disease [11, 12]. Serotype Ib and serotype II have also been reported in sporadic outbreaks from Middle Eastern aquaculture systems [13].

Table 1 summarizes the serotype and ST distribution across major tilapia-producing regions.

Table 1. Serotype and MLST Distribution of S. agalactiae in Farmed Tilapia

Data compiled from [6, 7, 8, 12].

The capsular polysaccharide is a key virulence factor. It inhibits complement-mediated opsonophagocytosis and is the primary target of protective antibodies. Capsule typing is therefore critical for vaccine formulation. Non-typeable isolates exist and may represent acapsular mutants or novel serotypes; these are often recovered from carrier fish or environmental samples [14].

Vaccine Development Strategies

Whole-Cell Inactivated Vaccines

Formalin-killed, whole-cell bacterins are the most widely used vaccine form in aquaculture. They are administered by intraperitoneal (i.p.) injection, immersion, or oral feed. Injected bacterins confer the highest protection (relative percent survival (RPS) of 70% to 90%) but are labor-intensive and not practical for small fry [15, 16]. Immersion vaccines provide moderate protection (RPS 40% to 60%) and are suitable for mass vaccination of fingerlings. Oral vaccines, while logistically attractive, typically yield lower and less uniform antibody titers due to antigen degradation in the foregut [17].

Adjuvantation is critical for whole-cell vaccines. Oil-adjuvanted bacterins produce a strong Th2-type response with prolonged IgM persistence, whereas aluminum hydroxide adjuvants are less effective in fish [18]. The choice of inactivant also affects immunogenicity; formalin treatment can destroy conformational epitopes on surface proteins, reducing cross-protection against heterologous serotypes.

Autogenous Vaccines

Autogenous (farm-specific) vaccines are formulated using bacterial isolates cultured from the target population. This approach is justified when local S. agalactiae strains differ antigenically from commercial vaccine strains. Autogenous bacterins are typically produced by a licensed facility using formalin inactivation and an oil adjuvant. Efficacy data from field trials indicate RPS values of 60% to 85% when the vaccine matches the outbreak serotype [19, 20]. However, the cost and regulatory hurdles limit their use to large integrated farms.

Selection of isolates for an autogenous vaccine requires thorough genotyping. Ideally, the vaccine strain should belong to the dominant ST and express the same capsular serotype as the field isolates. Cross-protection between serotypes Ia and III is minimal; vaccination with serotype Ia rarely protects against serotype III challenge [21]. A multivalent autogenous vaccine may incorporate two or three representative isolates from different STs.

Recombinant and Subunit Vaccines

Several surface-associated proteins have been explored as recombinant vaccine antigens: Sip (surface immunogenic protein), Bsp (bacillus surface protein), and the C5a peptidase ScpB. Sip, a conserved protein across GBS serotypes, induces IgG and IgM antibodies in fish and confers partial protection against lethal challenge (RPS 40% to 60%) [22, 23]. The alpha C protein (ACP) and Rib protein are also immunogenic but show serotype-specific protection [24].

DNA vaccines encoding the sip gene have been tested in tilapia with moderate success. Naked plasmid DNA injected intramuscularly elicits both humoral and cell-mediated responses, but translation to field use is hindered by the need for injection and regulatory concerns over plasmid integration [25].

The most promising subunit approach uses the capsular polysaccharide conjugated to a carrier protein (e.g., tetanus toxoid). CPS conjugate vaccines are highly immunogenic in mammals, but their high production cost and the need for serotype-specific formulations limit application in aquaculture [26].

Live Attenuated Vaccines

Spontaneously attenuated or genetically modified S. agalactiae strains have been evaluated. A streptomycin-dependent mutant that loses viability in drug-free water was tested as an immersion vaccine; it provided moderate protection but carried a risk of reversion to virulence [27]. Deletion mutants of the cpsE gene (capsule synthesis) are non-pathogenic and induce protective immunity in experimental trials, but regulatory approval for the release of live recombinant bacteria in aquaculture environments remains contentious [28].

Immunomodulation and Adjuvant Delivery

Nanoparticle-based delivery systems for killed or subunit antigens are under investigation. Chitosan nanoparticles encapsulating S. agalactiae whole-cell lysate enhance mucosal uptake when administered orally, improving RPS by 15% to 20% compared to free antigen [29]. Similarly, poly(lactic-co-glycolic acid) (PLGA) microspheres provide sustained release of antigen and reduce the need for booster doses. These technologies remain in the preclinical stage.

Vaccine Efficacy and Field Performance

Efficacy is assessed through laboratory challenge and field trials. Standardized challenge models use i.p. injection with a dose of 10^6 to 10^8 CFU per fish, with mortality recorded over 14 to 21 days. RPS is calculated using the formula: RPS = (1 - (% mortality vaccinated / % mortality control)) x 100. A RPS of 60% or greater is considered acceptable for licensing.

In field conditions, vaccine performance depends on water temperature, fish size, stress from handling, and nutrition. A meta-analysis of 15 vaccine trials in tilapia reported a mean RPS of 72.4% for i.p. injected bacterins, 53.1% for immersion, and 38.7% for oral administration [30]. Booster vaccination at 4 to 6 weeks after priming improves antibody persistence and RPS by 10% to 20% [31].

One major challenge is waning immunity over the grow-out cycle. Tilapia vaccinated at fingerling stage often lose protective titers by harvest size (500 to 800 grams). A single booster at mid-cycle is recommended for long-cycle production. Autogenous vaccines have shown more consistent field protection when the farm experiences persistent endemic disease due to a single ST [32].

Diagnostic and Genotyping Workflow

The decision tree for selecting a vaccine strain integrates prevalence data, genotyping, and in vitro cross-reactivity testing. Figure 1 presents a Mermaid diagram of the workflow.

flowchart TD
    A[Outbreak investigation], > B[Isolate S. agalactiae from moribund fish]
    B, > C[Identify by PCR cfb/sip]
    C, > D{Serotyping by latex agglutination or multiplex PCR}
    D, > E[MLST of representative isolates]
    E, > F[Compare ST with regional database]
    F, > G{ST matches vaccine strain?}
    G, >|Yes| H[Use commercial monovalent bacterin]
    G, >|No| I[Formulate autogenous vaccine]
    I, > J[Produce formalin-killed oil-adjuvanted bacterin]
    J, > K[Field efficacy trial]
    K, > L[Monitor mortality and antibody response]
    L, > M[Adjust formulation if RPS <60%]

The workflow underscores the importance of continuous surveillance. Shifts in ST prevalence necessitate periodic reassessment of vaccine composition.

Limitations and Future Directions

The reliance on serotype-based immunity is a fundamental limitation. S. agalactiae exhibits antigenic diversity even within a single serotype due to variations in surface protein expression. Next-generation vaccines targeting conserved antigens (e.g., Sip combined with capsular polysaccharide) may offer broader protection. Reverse vaccinology and pan-genome analyses have identified novel conserved antigens that elicit cross-protective responses in mice, but these have not yet been evaluated in fish [33, 34].

Antimicrobial resistance (AMR) is an emerging concern in S. agalactiae from aquaculture. Resistance to tetracyclines, macrolides, and chloramphenicol has been reported, mediated by tet(M), erm(B), and cat genes respectively [35]. Vaccination reduces the need for antibiotics, thus directly combating AMR. For a discussion of resistance in related aquatic pathogens, see Streptococcus iniae and Lactococcus garvieae Infections in Farmed Fish: Detection and Antimicrobial Stewardship.

Another challenge is vaccine delivery for small fry. Immersion vaccination is standard for fingerlings, but antigen uptake is inefficient. Mucosal adjuvants (e.g., CpG oligodeoxynucleotides, quillaja saponins) and bioencapsulation in Rotifers or Artemia are being tested to improve oral delivery [36, 37].

Conclusion

S. agalactiae remains the most significant bacterial pathogen in warm-water aquaculture, particularly in tilapia. Global prevalence is dominated by serotype Ia ST-103 clones, but regional variations require tailored vaccination strategies. MLST combined with capsule typing provides the necessary resolution for selecting appropriate vaccine strains. Autogenous bacterins offer a practical solution for farms with serotype mismatch to commercial vaccines, but the process requires genotypic confirmation and quality control. Continued investment in recombinant and multivalent subunit vaccines, coupled with improved mucosal delivery platforms, will reduce dependence on antibiotics and enhance sustainability of tilapia farming.

References

[1] Mian GF, Godoy DT, Leal CAG, et al. Aquaculture. 2009;294(1-2):1-6.

[2] Rao S, Karunasagar I, Karunasagar I. J Fish Dis. 2010;33(7):573-580.

[3] Evans JJ, Klesius PH, Pasnik DJ, et al. Dis Aquat Organ. 2008;78(3):217-225.

[4] Chideroli RT, Filippi D, da Silva MC, et al. Aquaculture. 2017;473:229-234.

[5] Kayansamruaj P, Pirarat N, Katagiri T, et al. J Fish Dis. 2014;37(8):739-748.

[6] Amal MNA, Zamri-Saad M. Aquac Res. 2011;42(8):1113-1122.

[7] Godoy DT, Mian GF, de Oliveira C, et al. J Clin Microbiol. 2013;51(11):3813-3817.

[8] Delannoy CMJ, Crumlish M, Fontaine MC, et al. BMC Genomics. 2013;14:140.

[9] Barkham T, Pearson T, Pond W, et al. Infect Genet Evol. 2018;58:207-214.

[10] Chen M, Wang R, Li LP, et al. Transbound Emerg Dis. 2021;68(4):2418-2430.

[11] Liu G, Wang R, Chen M, et al. Microb Pathog. 2020;148:104444.

[12] Suanyuk N, Kong F, Ko D, et al. Dis Aquat Organ. 2008;81(2):113-120.

[13] Najiah M, Rahim MD, Lee KL, et al. J Anim Vet Adv. 2014;13(3):147-153.

[14] Oliveira ST, da Silva FA, de Oliveira AL, et al. Microb Pathog. 2022;165:105482.

[15] Pasnik DJ, Evans JJ, Klesius PH. Vaccine. 2005;23(18):2350-2356.

[16] Klesius PH, Shoemaker CA, Evans JJ. Dev Biol Stand. 2000;104:113-122.

[17] Trung NB, Hien DH, Cam DT, et al. Fish Shellfish Immunol. 2011;31(6):1147-1153.

[18] Griffiths DW, Lumsden JS, Hines ME, et al. Vaccine. 2013;31(9):1337-1343.

[19] LaFrentz BR, Shoemaker CA, Klesius PH. J Aquat Anim Health. 2011;23(3):120-126.

[20] Crumlish M, Thanh PC, Jian L, et al. J Fish Dis. 2017;40(12):1775-1783.

[21] Choresca CH, Gomez DK, Kim JH, et al. Dis Aquat Organ. 2009;87(3):213-219.

[22] Cheng S, Hu Y, Zhang Z, et al. Fish Shellfish Immunol. 2015;44(1):227-233.

[23] Huang BF, Chen YL, Chen MM, et al. Vaccine. 2017;35(49):6891-6898.

[24] Lin J, Wang G, Li W, et al. Fish Shellfish Immunol. 2018;81:146-153.

[25] Yao L, Li X, Zhang J, et al. Vaccine. 2018;36(40):5959-5966.

[26] Paoletti LC, Wessels MR, Kasper DL. J Infect Dis. 1992;166(6):1416-1419.

[27] Pasnik DJ, Evans JJ, Klesius PH. J Fish Dis. 2006;29(4):241-247.

[28] Li LP, Wang R, Chen M, et al. Vaccine. 2019;37(43):6407-6414.

[29] Zhu B, Song Z, Zhao Z, et al. Fish Shellfish Immunol. 2020;98:816-824.

[30] Ma YP, Ke H, Liang ZL, et al. Aquaculture. 2021;533:736213.

[31] Shoemaker CA, LaFrentz BR, Klesius PH. J Fish Dis. 2013;36(4):399-407.

[32] Ngo TP, Crumlish M, Rampersad JN, et al. Vaccine. 2021;39(10):1522-1530.

[33] Maione D, Margarit I, Rinaudo CD, et al. Science. 2005;309(5731):148-150.

[34] Pasquini P, Pavone M, De Angelis M, et al. Vaccine. 2019;37(4):616-623.

[35] Weiss M, Gorniak M, Nies DH, et al. Microb Drug Resist. 2020;26(8):936-945.

[36] Scolea LC, de Oliveira ST, da Silva FA, et al. Fish Shellfish Immunol. 2022;123:214-222.

[37] Liu Y, Li J, Gui L, et al. Fish Shellfish Immunol. 2023;132:108495.

[38] Evans JJ, Klesius PH, Shoemaker CA. Aquac Res. 2003;34(4):277-285.

[39] Siti Zahrah AS, Ariff N, Amal MNA, et al. J Fish Dis. 2012;35(9):673-681.

[40] Jantama K, Jantama SS, Kanjanavas P, et al. Aquaculture. 2015;448:149-155.

[41] Pumipuntu N, Sunthornthumkasem S, Indrawattana N, et al. J Infect Dev Ctries. 2019;13(5):431-438.

[42] Li J, Wang R, Chen M, et al. J Fish Dis. 2020;43(11):1385-1394.

[43] Tan Y, Ho BC, Zhang Y, et al. Vaccine. 2022;40(3):490-498.

[44] Bui HT, Bui TY, Nguyen TD, et al. J Fish Dis. 2023;46(2):177-187.

[45] Abdel-Latif HMR, Soliman MK, El-Banna NI, et al. Aquac Int. 2023;31(1):225-242.

[46] Shahin K, Shinn AP, Soad AA, et al. J Aquat Anim Health. 2024;36(1):45-55.

[47] Song W, Li J, Guo Z, et al. Fish Shellfish Immunol. 2021;112:1-8.

[48] Wang Y, Sun L, Zhang Y, et al. Microb Pathog. 2022;162:105348.

[49] Kulkarni A, Swaminathan TR, Gupta S, et al. Aquaculture. 2023;562:738844.

[50] Das S, Patra A, Nayak KK, et al. Rev Aquac. 2024;16(2):875-891.